

# Genetic risk factors of Alzheimer's disease and cell-to-cell transmission of Tau

Riikka-Liisa Uronen and Henri J. Huttunen

*Neuroscience Center, University of Helsinki, FI-00014 Helsinki, Finland*

## Article Info

### Article Notes

Received: May 04, 2016

Accepted: May 18, 2016

### \*Correspondence:

Dr. Henri J. Huttunen

Neuroscience Center

P.O. Box 56 (Viikinkaari 4), FI-00014

University of Helsinki, Finland

Telephone: +358 2941 57616

Fax number: +358 2941 57620

Email: [Henri.Huttunen@helsinki.fi](mailto:Henri.Huttunen@helsinki.fi)

© 2016 Huttunen HJ. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License

### Keywords

Neurodegeneration

Tauopathy

Dementia

Polarity Signaling

Synaptic Vesicle

Functional Genomics

## ABSTRACT

In Alzheimer's disease (AD), loss of neurons and synapses parallels the formation of neurofibrillary tangles, protein aggregates mainly composed of hyperphosphorylated and aggregated Tau protein. Tau is mostly a cytosolic protein but can also be secreted by neurons. Cell-to-cell transfer of misfolded Tau protein plays a key role in the spread of neurofibrillary pathology between brain regions in AD and other tauopathies. Advances in genome-wide technologies have identified a large number of genetic risk factors for late-onset AD (LOAD). Currently, it remains unknown if genetic factors influence disease risk or progression rate by altering cell-to-cell propagation of Tau. Several LOAD risk genes are functionally associated with endocytic trafficking providing a potential link to Tau secretion and uptake. Recently, a LOAD risk gene FRMD4A was shown to regulate Tau secretion via a pathway linked to presynaptic vesicle machinery and polarity signaling. Tau release is linked to neuronal activity, and genetic factors that affect presynaptic vesicle release in the aging brain may also influence disease progression in AD and other tauopathies. In this mini review, we summarize the recent literature with a focus on the role of FRMD4A-cytohesin-Arf6 pathway and presynaptic vesicle machinery in the secretion of Tau.

## Cell-to-cell Propagation of Tau in Alzheimer's Disease and other Tauopathies

Tau pathology in AD progresses through anatomically connected brain regions, beginning in the transentorhinal region, then involving the hippocampus and finally the neocortex<sup>1</sup>. The number and distribution of neurofibrillary tangles (NFTs) is strongly correlated with progressive cognitive loss in AD and most other tauopathies.

Tau, a cytosolic microtubule-associated protein, can be released from cells, including neurons, under physiological conditions<sup>2</sup>. Misfolded and aggregated Tau has been reported to transfer between neighboring cells in vitro<sup>3-5</sup> and in vivo<sup>6-8</sup>. Multiple other proteins associated with neurodegenerative diseases, including amyloid- $\beta$  peptide (A $\beta$ ),  $\alpha$ -synuclein, mutant SOD1, mutant huntingtin and TDP-43, have also been shown to propagate protein misfolding pathology between cells in a similar prion-like manner, although the respective neuropathological cascades may vary in the human brain (reviewed in<sup>9,10</sup>). How the accumulation and spreading of A $\beta$  and Tau aggregates are mechanistically connected in human AD brain remains largely a mystery<sup>11</sup>. Clearly, however, Tau pathology can develop and spread in the absence of A $\beta$  plaques, as evidenced by numerous tauopathies, such as familial cases of frontotemporal dementia that are primarily driven by aggregation-promoting mutations in the *MAPT* gene (that encodes the Tau protein)<sup>12</sup>. Also, there is an on-going debate whether primary age-related tauopathy (PART), an A $\beta$ -independent temporal lobe NFT pathology frequently observed in the brains of aged individuals, is a separate disease entity from AD<sup>13,14</sup>.

While the cell-to-cell transmission paradigm now appears to explain how the neurodegenerative pathology spreads between brain regions, the cellular mechanisms of secretion and uptake of misfolded intracellular proteins remain incompletely understood. Conformational templating, a characteristic of amyloids in general, drives the seeding and accumulation of pathological protein aggregates<sup>9,10</sup>. Interestingly, specific conformations and strains with distinct propagation properties have been described for Tau<sup>5</sup>. It is currently unclear whether the release of Tau species from neurons is related to a normal physiological release pathway, unconventional secretory mechanisms or mechanisms related to neuronal injury. Cellular uptake of Tau fibrils has been shown to involve binding to heparan sulphate proteoglycans on the cell surface followed by macropinocytosis<sup>15</sup>, an actin-dependent endocytic process that allows the entry of fluid-phase macromolecular structures into the cell. However, membrane turnover in neurons is tightly controlled, and basal macropinocytotic activity in mature neurons appears to be rather low<sup>16</sup>. Additional stimulation, such as axonal injury, may be required to promote neuronal uptake of protein aggregates via macropinocytosis. Importantly,

microglial cells facilitate Tau propagation in vivo by packing phagocytosed Tau to exosomes that are more effectively taken up by neurons than vesicle-free Tau species<sup>17</sup>.

## Do Genetic Risk Factors of Late-onset Alzheimer's Disease affect Disease Risk or Progression Rate by Altering Tau Propagation?

Early-onset AD is an almost entirely genetically determined disease, characterized by highly penetrant disease-causing mutations in three genes (*APP*, *PSEN1* and *PSEN2*) that are all functionally linked to generation of amyloid- $\beta$  peptide<sup>18</sup>. In contrast, LOAD is a complex disorder with heterogeneous etiology, and variable age of onset and progression rate. The *APOE* gene (encoding apolipoprotein E) is a major genetic risk factor for LOAD<sup>19</sup>. Genome-wide association studies (GWAS) have identified a large number of common risk variants within >20 genetic loci associated with LOAD<sup>20-25</sup>, including *CLU*, *ABCA7*, *CD2AP*, *BIN1*, *CR1*, *CD33* and the *MS4A* gene cluster<sup>20-25</sup>. Next-generation sequencing efforts have identified additional rare variants with strong effects on disease risk, including *TREM2* and *ABCA7*<sup>26-29</sup>. In addition, genome-wide association studies have linked *FRMD4A* gene to LOAD<sup>21</sup> and late-life cognitive decline<sup>30</sup>. Although the exact functional roles of individual susceptibility genes remain poorly understood, the main LOAD-associated genetic loci appear to be functionally linked to three major biological pathways: immune system, lipid metabolism and cell membrane processes (e.g. endocytosis, synaptic function)<sup>31,32</sup>.

Significantly increased levels of Tau in the cerebrospinal fluid (CSF) are associated with faster rate of cognitive decline and overall worse clinical outcome in AD<sup>33,34</sup>. In general, alleles associated with lower CSF Tau levels would thus be considered protective for disease risk, associated with less tau pathology and with slower cognitive decline, and vice versa. In support of this, genetic variants linked to increased CSF phospho-Tau (Thr181) levels were also associated with faster rate of disease progression while having no effect on disease risk or age of onset<sup>35</sup>. In particular, a single-nucleotide polymorphism (SNP; rs1868402) in the *PPP3R1* gene linked to reduced parietal lobe expression of protein phosphatase B (calcineurin), a known Tau phosphatase, was associated with higher CSF phospho-Tau levels and faster rate of disease progression. Another genome-wide association study that used CSF Tau levels as an endophenotype of LOAD identified novel risk variants of the disease, including *SNAR-1*, *GLIS3* and *TOMM40*, and confirmed the association of *APOE* and *TREM2* with the variability of CSF Tau and phospho-Tau levels<sup>36</sup>. These studies clearly indicate that common genetic variants have an impact on the CSF levels of Tau and that this may be associated with the risk of LOAD or rate of disease progression. Interestingly, none of the SNPs linked to altered CSF levels of Tau were associated with

Tau (*MAPT*) expression levels suggesting that they affect CSF Tau levels by a post-transcriptional mechanism, which could potentially include mechanisms regulating cellular release and uptake of Tau.

### How are the Risk Genes Connected to Pathogenic Mechanisms in LOAD?

Despite the rapidly accumulating genetic data, there remains a knowledge gap regarding the functional association of the risk genes and gene variants to the pathobiology of complex diseases. Single nucleotide polymorphisms that act as expression quantitative trait loci (eQTL) influencing gene expression constitute an important class of functional variants of genes. Several LOAD-associated risk variants, such as *CLU*, *MS4A4A* and *ABCA7*, harbor eQTLs<sup>37</sup>. Recently, transcriptional analysis of Braak-staged temporal cortex samples from AD patients and healthy controls revealed that the expression of *FRMD4A*, *MS4A6A*, *CLU* and *TREM2* was altered in relation to increasing AD-related neurofibrillary pathology<sup>38</sup>.

To gain more insight into the functional roles of LOAD risk genes, we combined individual silencing of selected LOAD risk genes (*APOE*, *BIN1*, *CLU*, *ABCA7*, *CR1*, *PICALM*, *CD33*, *CD2AP*, *FRMD4A* and *TREM2*; based on LOAD genetics meta-analyses<sup>39</sup> and recent literature), together with AD pathobiology-based pathway analysis. We previously developed a panel of sensitive live-cell assays for monitoring changes of pathologically central protein-protein interactions in AD, such as key protein interactions related to A $\beta$  generation and Tau hyperphosphorylation<sup>38,40,41,42</sup>. In combination with RNAi silencing of LOAD susceptibility genes, the AD-specific pathway sensors provide an easily accessible platform for studying functional roles of LOAD risk genes in live cells.

While the expression of *FRMD4A* was found to be decreased in relation to increasing neurofibrillary pathology in the temporal cortex of LOAD patients, in vitro pathway analysis showed that reduced *FRMD4A* expression associates with both increased amyloidogenic amyloid precursor protein (APP) processing and increased Tau phosphorylation activity<sup>38</sup>. Furthermore, our recent study showed that altered *FRMD4A* level also significantly alters Tau secretion<sup>41</sup>, for the first time functionally linking a LOAD risk gene to basic cellular mechanisms of cell-to-cell transfer of Tau. None of the other top-ten LOAD risk genes included in this study showed a functional connection to Tau secretion. *APOE* knockdown caused a subtle increase in cellular uptake of Tau, an effect possibly related to the direct interaction of ApoE and Tau proteins<sup>43</sup> in the extracellular space.

### FRMD4A, Cytohesin and Cell Polarity Signaling Modulate Tau Secretion

FRMD4A (FERM Domain Containing 4A) protein is

involved in polarization of epithelial cells<sup>44</sup> and mutations in the *FRMD4A* gene lead to microcephaly and mental retardation in humans<sup>45</sup>. However, most of the physiological functions of *FRMD4A* are so far unclear. Our data clearly suggests that *FRMD4A*-cytohesin-Arf6 pathway regulates Tau secretion<sup>41</sup>. Activation of this pathway in HEK293T cells by overexpressing *FRMD4A* or Arf6 leads to increased Tau secretion, whereas inhibition by *FRMD4A* RNAi or cytohesin inhibitor SecinH3 decreased it. Surprisingly, this effect was opposite in cortical neuron cultures, where inhibition of this pathway lead to an increase in Tau secretion. The significant increase of neuronal Tau secretion by *FRMD4A*/cytohesin inhibition suggests that the reduced *FRMD4A* levels in AD brain may be causally linked to spreading of Tau pathology.

Cytohesins<sup>a</sup> are a family of Arf Guanine Nucleotide Exchange Factors (GEFs) that have a central Sec7-GEF-domain, a protein-protein interaction mediating coiled coil (CC) domain and a membrane targeting pleckstrin homology (PH) domain. Cytohesins bind *FRMD4A*<sup>44</sup> and activate the small GTPase Arf6<sup>46</sup> promoting its translocation to the plasma membrane<sup>47</sup>. Cytohesins function in various cellular processes including insulin receptor signaling<sup>48</sup>, integrin trafficking and cell migration<sup>46</sup>. Importantly, they also regulate neurotransmission<sup>47</sup> and membrane trafficking<sup>49</sup> at the presynaptic terminal, probably via their interaction with Munc13s<sup>50</sup>, that are proteins essential for synaptic vesicle priming<sup>51</sup>. As Tau secretion is related to neurotransmitter release<sup>2,52</sup>, it seems plausible that the changes we see in Tau secretion with modulation of *FRMD4A*-cytohesin pathway are connected to synaptic vesicle release. The extreme specialization of the presynaptic terminal may also explain why the effect of the *FRMD4A*-cytohesin pathway is different in neurons and in HEK293T cells<sup>51</sup>.

The polarity signaling complex Par3/Par6/aPKC $\zeta$  (Partitioning defective 3, Partitioning defective 6 and atypical Protein Kinase C  $\zeta$ , respectively), that associates with *FRMD4A* and regulates its activity in epithelial cells<sup>44</sup> also affects Tau secretion<sup>41</sup> (Figure 1). To our knowledge this is the first study implicating a link between cell polarity signaling and Tau secretion. As neurons are highly polarized cells, polarity signaling is not only important for their development and differentiation<sup>53</sup> but also may play a role in plasticity<sup>54</sup>. In addition, polarity signaling proteins have a more general role in endocytic trafficking<sup>55</sup>, which may also lead to changes in Tau release.

In addition to Tau phosphorylation<sup>38</sup> and secretion<sup>41</sup>, *FRMD4A* also affects A $\beta$  secretion<sup>38</sup>. Notably, the secretion


<sup>a</sup>Cytohesin family aliases:

Cytohesin 1 = mSec7-1, PSCD-1,

Cytohesin 2 = mSec7-2, ARNO, PSCD-2

Cytohesin 3 = mSec7-3, GRP-1, PSCD-3

Cytohesin 4 = PSCD-4



**Figure 1. The role of FRMD4A-cytohesin-Arf6 pathway in presynaptic release of Tau.** Tau, a cytosolic microtubule regulating protein, is released from cells in association with neuronal activity. The polarity signaling complex Par3/Par6/aPKC $\zeta$  regulates the activity of FRMD4A and cytohesins, which upon activation promote membrane localization of Arf6 and also interact with Munc13s, key regulators of synaptic vesicle (SV) priming. Activity of this signaling module regulates the release of Tau from the presynaptic terminal to the extracellular space. Tau release is enhanced by reduced expression of FRMD4A (RNA interference mimicking the decreased FRMD4A levels in LOAD patients) or with the cytohesin inhibitor SecinH3.

of A $\beta$  into the extracellular space is also tightly regulated by neuronal activity *in vitro*<sup>56</sup> and *in vivo*<sup>57</sup>. Whether A $\beta$  secretion is similarly regulated with cytohesin/Arf6 and Par3/Par6/aPKC $\zeta$  remains to be studied. Interestingly, cytohesins were recently also associated with another neurodegenerative disease, amyotrophic lateral sclerosis (ALS)<sup>58</sup>, but whether this is related to our findings needs to be further investigated.

### Conclusions

LOAD risk genes involved in endocytic trafficking, synaptic function and microglial activity may affect AD risk and progression through regulation of cellular secretion and uptake of Tau. The expression of LOAD risk gene *FRMD4A* is decreased in Alzheimer's disease patient brains, and a decrease in *FRMD4A* protein level leads to an increase of neuronal Tau secretion. Based on these results, we suggest that a presynaptic signaling module consisting

of *FRMD4A*, cytohesins and Arf6 acts as a regulator of cell-to-cell transmission of Tau.

### Acknowledgements

This work was supported by grants from the Academy of Finland (grants 218081, 263762), the University of Helsinki Funds and Finnish Cultural Foundation.

### References

1. Braak H, Braak E. Neuropathological staging of alzheimer-related changes. *Acta neuropathologica*. 1991; 82: 239-259.
2. Pooler AM, Phillips EC, Lau DH, Noble W, Hanger DP. Physiological release of endogenous tau is stimulated by neuronal activity. *EMBO reports*. 2013; 14: 389-394.
3. Frost B, Jacks RL, Diamond MI. Propagation of tau misfolding from the outside to the inside of a cell. *The Journal of biological chemistry*. 2009; 284: 12845-12852.
4. Kfoury N, Holmes BB, Jiang H, Holtzman DM, Diamond MI. Transcellular propagation of tau aggregation by fibrillar species. *The Journal of biological chemistry*. 2012; 287: 19440-19451.



5. Sanders DW, Kaufman SK, DeVos SL, Sharma AM, Mirbaha H, et al. Distinct tau prion strains propagate in cells and mice and define different tauopathies. *Neuron*. 2014; 82: 1271-1288.
6. de Calignon A, Polydoro M, Suarez-Calvet M, William C, Adamowicz DH, et al. Propagation of tau pathology in a model of early alzheimer's disease. *Neuron*. 2012; 73: 685-697.
7. Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, et al. Transmission and spreading of tauopathy in transgenic mouse brain. *Nature cell biology*. 2009; 11: 909-913.
8. Iba M, Guo JL, McBride JD, Zhang B, Trojanowski JQ, et al. Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of alzheimer's-like tauopathy. *Journal of Neuroscience*. 2013; 33: 1024-1037.
9. Brettschneider J, Del Tredici K, Lee VM, Trojanowski JQ. Spreading of pathology in neurodegenerative diseases: A focus on human studies. *Nature reviews Neuroscience*. 2015; 16: 109-120.
10. Jucker M, Walker LC. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. *Nature*. 2013; 501: 45-51.
11. Eisele YS, Duyckaerts C. Propagation of ass pathology: Hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. *Acta neuropathologica*. 2016; 131:5-25.
12. Iqbal K, Liu F, Gong CX. Tau and neurodegenerative disease: The story so far. *Nature reviews Neurology*. 2016; 12:15-27.
13. Cray JF, Trojanowski JQ, Schneider JA, Abisambra JF, Abner EL, et al. Primary age-related tauopathy (part): A common pathology associated with human aging. *Acta neuropathologica*. 2014; 128: 755-766.
14. Duyckaerts C, Braak H, Brion JP, Buee L, Del Tredici K, et al. Part is part of alzheimer disease. *Acta neuropathologica*. 2015; 129: 749-756.
15. Holmes BB, DeVos SL, Kfoury N, Li M, Jacks R, et al. Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. *Proceedings of the National Academy of Sciences*. 2013; 110: E3138-3147.
16. Zeineddine R, Yerbury JJ. The role of macropinocytosis in the propagation of protein aggregation associated with neurodegenerative diseases. *Frontiers in physiology*. 2015; 6: 277.
17. Asai H, Ikezu S, Tsunoda S, Medalla M, Luebke J, et al. Depletion of microglia and inhibition of exosome synthesis halt tau propagation. *Nature neuroscience*. 2015; Doi: 10.1038/nn.4132
18. Cacace R, Sleegers K, Van Broeckhoven C. Molecular genetics of early-onset alzheimer disease revisited. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2016; Doi: 10.1016/j.jalz.2016.01.012.
19. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, et al. Gene dose of apolipoprotein e type 4 allele and the risk of alzheimer's disease in late onset families. *Science*. 1993; 261: 921-923.
20. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, et al. Genome-wide association study identifies variants at *CLU* and *PICALM* associated with alzheimer's disease. *Nature genetics*. 2009; 41: 1088-1093.
21. Lambert JC, Grenier-Boley B, Harold D, Zelenika D, Chouraki V, et al. Genome-wide haplotype association study identifies the *FRMD4A* gene as a risk locus for alzheimer's disease. *Molecular psychiatry*. 2013; 18: 461-470.
22. Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, et al. Common variants at *ABCA7*, *MS4A6A/MS4A4E*, *EPHA1*, *CD33* and *CD2AP* are associated with alzheimer's disease. *Nature genetics*. 2011; 43: 429-435.
23. Lambert JC, Heath S, Even G, Campion D, Sleegers K, et al. Genome-wide association study identifies variants at *CLU* and *CR1* associated with alzheimer's disease. *Nature genetics*. 2009; 41: 1094-1099.
24. Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, et al. Common variants at *MS4A4/MS4A6E*, *CD2AP*, *CD33* and *EPHA1* are associated with late-onset alzheimer's disease. *Nature genetics*. 2011; 43: 436-441.
25. Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gudnason V, et al. Genome-wide analysis of genetic loci associated with alzheimer disease. *The Journal of the American Medical Association*. 2010; 303: 1832-1840.
26. Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, et al. Variant of *TREM2* associated with the risk of alzheimer's disease. *The New England journal of medicine*. 2013; 368: 107-116.
27. Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, et al. *TREM2* variants in alzheimer's disease. *The New England journal of medicine*. 2013; 368: 117-127.
28. Steinberg S, Stefansson H, Jonsson T, Johannsdottir H, Ingason A, et al. Loss-of-function variants in *ABCA7* confer risk of alzheimer's disease. *Nature genetics*. 2015; 47: 445-447.
29. Cuyvers E, De Roeck A, Van den Bossche T, Van Cauwenberghe C, Bettens K, et al. Mutations in *ABCA7* in a belgian cohort of alzheimer's disease patients: A targeted resequencing study. *The Lancet Neurology*. 2015; 14: 814-822.
30. Andrews SJ, Das D, Cherbuin N, Anstey KJ, Eastale S. Association of genetic risk factors with cognitive decline: The path through life project. *Neurobiology of aging*. 2016; 41: 150-158.
31. Bettens K, Sleegers K, Van Broeckhoven C. Genetic insights in alzheimer's disease. *The Lancet Neurology*. 2013; 12: 92-104.
32. Karch CM, Goate AM. Alzheimer's disease risk genes and mechanisms of disease pathogenesis. *Biological psychiatry*. 2015; 77: 43-51.
33. Kester MI, van der Vlies AE, Blankenstein MA, Pijnenburg YA, van Elk EJ, et al. *CSF* biomarkers predict rate of cognitive decline in alzheimer disease. *Neurology*. 2009; 73: 1353-1358.
34. Wallin AK, Blennow K, Zetterberg H, Londos E, Minthon L, et al. *CSF* biomarkers predict a more malignant outcome in alzheimer disease. *Neurology*. 2010; 74: 1531-1537.
35. Cruchaga C, Kauwe JS, Mayo K, Spiegel N, Bertelsen S, et al. *SNPs* associated with cerebrospinal fluid phospho-tau levels influence rate of decline in alzheimer's disease. *PLoS Genetics*. 2010; 6: e1001101.
36. Cruchaga C, Kauwe JS, Harari O, Jin SC, Cai Y, et al. *Gwas* of cerebrospinal fluid tau levels identifies risk variants for alzheimer's disease. *Neuron*. 2013; 78: 256-268.
37. Allen M, Zou F, Chai HS, Younkin CS, Crook J, et al. Novel late-onset alzheimer disease loci variants associate with brain gene expression. *Neurology*. 2012; 79: 221-228.
38. Martiskainen H, Viswanathan J, Nykanen NP, Kurki M, Helisalmi S, et al. Transcriptomics and mechanistic elucidation of alzheimer's disease risk genes in the brain and in vitro models. *Neurobiology of aging*. 2015; 36: 1221 e1215-1228.
39. Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. Systematic meta-analyses of alzheimer disease genetic association studies: The *ALZGENE* database. *Nature genetics*. 2007; 39: 17-23.
40. Merezhko M, Muggalla P, Nykanen NP, Yan X, Sakha P, et al. Multiplex assay for live-cell monitoring of cellular fates of amyloid-beta precursor protein (APP). *PLoS one*. 2014; 9: e98619
41. Yan X, Nykanen NP, Brunello CA, Haapasalo A, Hiltunen M, et al. *FRMD4A*-cytohesin signaling modulates cellular release of tau. *Journal of cell science*. 2016; Doi: 10.1242/jcs.180745
42. Remy I, Michnick SW. A highly sensitive protein-protein interaction assay based on *GAUSSIA* luciferase. *Nature methods*. 2006; 3: 977-979.
43. Strittmatter WJ, Saunders AM, Goedert M, Weisgraber KH, Dong LM, et al. Isoform-specific interactions of apolipoprotein e with microtubule-associated protein tau: Implications for alzheimer disease. *Proc Natl Acad Sci U S A*. 1994; 91: 11183-11186.

44. Ikenouchi J, Umeda M. Frmd4a regulates epithelial polarity by connecting arf6 activation with the par complex. *Proceedings of the National Academy of Sciences*. 2010; 107: 748-753.
45. Fine D, Flusser H, Markus B, Shorer Z, Gradstein L, et al. A syndrome of congenital microcephaly, intellectual disability and dysmorphism with a homozygous mutation in frmd4a. *European journal of human genetics: EJHG*. 2014;10.1038/ejhg.2014.241
46. Kolanus W. Guanine nucleotide exchange factors of the cytohesin family and their roles in signal transduction. *Immunological reviews*. 2007; 218: 102-113.
47. Ashery U, Koch H, Scheuss V, Brose N, Rettig J. A presynaptic role for the adp ribosylation factor (arf)-specific gdp/gtp exchange factor msec7-1. *Proceedings of the National Academy of Sciences*. 1999; 96: 1094-1099.
48. Hafner M, Schmitz A, Grune I, Srivatsan SG, Paul B, et al. Inhibition of cytohesins by secinh3 leads to hepatic insulin resistance. *Nature*. 2006; 444: 941-944.
49. Tagliatti E, Fadda M, Falace A, Benfenati F, Fassio A. Arf6 regulates the cycling and the readily releasable pool of synaptic vesicles at hippocampal synapse. *eLife*. 2016; Doi: 10.7554/eLife.10116
50. Neeb A, Koch H, Schurmann A, Brose N. Direct interaction between the arf-specific guanine nucleotide exchange factor msec7-1 and presynaptic munc13-1. *European journal of cell biology*. 1999; 78: 533-538
51. Sudhof TC. The presynaptic active zone. *Neuron*. 2012; 75: 11-25.
52. Yamada K, Holth JK, Liao F, Stewart FR, Mahan TE, et al. Neuronal activity regulates extracellular tau in vivo. *The Journal of experimental medicine*. 2014; 211: 387-393.
53. Arimura N, Kaibuchi K. Neuronal polarity: From extracellular signals to intracellular mechanisms. *Nature reviews Neuroscience*. 2007; 8: 194-205.
54. Zhang H. Polarity determinants in dendritic spine development and plasticity. *Neural plasticity*. 2016; 2016: 3145019.
55. Balklava Z, Pant S, Fares H, Grant BD. Genome-wide analysis identifies a general requirement for polarity proteins in endocytic traffic. *Nature cell biology*. 2007; 9: 1066-1073.
56. Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, et al. App processing and synaptic function. *Neuron*. 2003; 37: 925-937.
57. Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, et al. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. *Neuron*. 2005; 48: 913-922.
58. Zhai J, Zhang L, Mojsilovic-Petrovic J, Jian X, Thomas J, et al. Inhibition of cytohesins protects against genetic models of motor neuron disease. *Journal of Neuroscience*. 2015; 35: 9088-9105.